Nivolumab with a special dye for head and neck cancer surgery
Treatments studied
Part of Cancer, Mouth & dental clinical trials.
This trial tests if a special dye attached to the drug nivolumab can help surgeons see cancer cells more clearly during surgery. If you have head and neck cancer and are scheduled for surgery, this study might be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have head and neck cancer that is confirmed by biopsy or imaging, or you are planning surgery for suspected cancer.
- Your overall health and organ function must be good enough for surgery and anesthesia.
- You must be able to perform daily activities with minimal help (Karnofsky score 70% or higher or ECOG 0-2).
- You must not have an active autoimmune disease, certain infections, or take high-dose steroids (more than 10 mg of prednisone daily).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special fluorescent dye attached to panitumumab, a cancer-targeting antibody, to help surgeons see tumor tissue more clearly during head and neck cancer surgery. The goal is to improve removal of all cancer cells while sparing healthy tissue.
This trial tests a new way to give an immunotherapy drug called nivolumab before surgery for head and neck cancer. The drug is injected directly into the tumor and is labeled with a fluorescent marker so researchers can see how it works in the removed tissue. This might help improve treatment for future patients.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests if a special dye attached to the immunotherapy drug nivolumab can help surgeons see tumor cells during surgery for high grade glioma. You may join if you are scheduled for surgery and your organs are working well.
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.